Skip to main content
SpringerLink
Log in

Kribbeln, Jucken, Brennen in den Beinen

Aktuelle Diagnose- und Therapieoptionen des Restless-Legs-Syndroms

  • zertifizierte fortbildung
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

Zusammenfassung

Das Restless Legs Syndrom (RLS) führt zu einer erheblichen Beeinträchtigung des Schlafs, und ist in bis zu 80 % der Fälle mit einer signifikanten Tagesmüdigkeit verbunden. Neben familiären und genetischen Ursachen gibt es symptomatische Formen. Zugrunde liegt eine Störung des Eisen- und Dopaminstoffwechsels. Therapeutisch sind neben Levodopa auch Dopaminrezeptoragonisten zugelassen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Oertel WH, Deuschl G, Poewe W. Parkinson-Syndrome und andere Bewegungsstörungen. Stuttgart, New York: Thieme; 2012

  2. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165(11):1286–92

    Article  Google Scholar 

  3. Ghorayeb I, Tison F. [Epidemiology of restless legs syndrome]. Rev Neurol 2009;165(8-9):641–9

    Article  CAS  Google Scholar 

  4. Whittom S, Dauvilliers Y, Pennestri MH, Vercauteren F, Molinari N, Petit D, et al. Age-at-onset in restless legs syndrome: a clinical and polysomnographic study. Sleep Med 2007;9(1):54–9

    Article  CAS  Google Scholar 

  5. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23(16):2267–302

    Article  Google Scholar 

  6. Wijemanne S, Ondo W. Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management. Pract Neurol 2017;17(6):444–52

    Article  Google Scholar 

  7. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria — history, rationale, description, and significance. Sleep Med 2014;15(8):860–73

    Article  Google Scholar 

  8. Ferri R, Manconi M, Plazzi G, Bruni O, Cosentino FI, Ferini-Strambi L, et al. Leg movements during wakefulness in restless legs syndrome: time structure and relationships with periodic leg movements during sleep. Sleep Med 2012;13(5):529–35

    Article  Google Scholar 

  9. Trenkwalder C, Allen R, Hogl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology 2016;86(14):1336–43

    Article  CAS  Google Scholar 

  10. Li Y, Munger KL, Batool-Anwar S, De Vito K, Ascherio A, Gao X. Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women. Neurology 2012;78(19):1500–6

    Article  CAS  Google Scholar 

  11. Vavrova J, Kemlink D, Sonka K, Havrdova E, Horakova D, Pardini B, et al. Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study. Sleep Med 2012;13(7):848–51

    Article  CAS  Google Scholar 

  12. Rana AQ, Siddiqui I, Mosabbir A, Athar A, Syed O, Jesudasan M, et al. Association of pain, Parkinson‘s disease, and restless legs syndrome. J Neurol Sci 2013;327(1-2):32–4

    Article  Google Scholar 

  13. Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of Restless Legs Syndrome in Parkinson‘s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord 2013;19(4):426–30

    Article  Google Scholar 

  14. Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology 2009;72(11):955–60

    Article  Google Scholar 

  15. Nineb A, Rosso C, Dumurgier J, Nordine T, Lefaucheur JP, Creange A. Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. Eur J Neurol 2007;14(7):788–92

    Article  CAS  Google Scholar 

  16. Katsi V, Katsimichas T, Kallistratos MS, Tsekoura D, Makris T, Manolis AJ, et al. The association of Restless Legs Syndrome with hypertension and cardiovascular disease. Med Sci Monit 2014;20:654–9

    Article  Google Scholar 

  17. Srivanitchapoom P, Pandey S, Hallett M. Restless legs syndrome and pregnancy: a review. Parkinsonism Relat Disord 2014;20(7):716–22

    Article  Google Scholar 

  18. Klingelhoefer L, Bhattacharya K, Reichmann H. Restless legs syndrome. Clin Med 2016;16(4):379–82

    Article  Google Scholar 

  19. Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 2018;41:27–44

    Article  Google Scholar 

  20. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JAG. Genetics of restless legs syndrome: An update. Sleep Med Rev 2018;39:108–21

    Article  Google Scholar 

  21. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39(8):1000–6

    Article  CAS  Google Scholar 

  22. Yang Q, Li L, Chen Q, Foldvary-Schaefer N, Ondo WG, Wang QK. Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population. Sleep Med 2011;12(8):800–4

    Article  Google Scholar 

  23. Lin CH, Chen ML, Wu VC, Li WY, Sy HN, Wu SL, et al. Association of candidate genetic variants with restless legs syndrome in end stage renal disease: a multicenter case-control study in Taiwan. Eur J Neurol 2014;21(3):492–8

    Article  CAS  Google Scholar 

  24. Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357(7):639–47

    Article  CAS  Google Scholar 

  25. Moore HT, Winkelmann J, Lin L, Finn L, Peppard P, Mignot E. Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD. Sleep 2014;37(9):1535–42

    Article  Google Scholar 

  26. Kim MK, Cho YW, Shin WC, Cho JW, Shon YM, Kim JH, et al. Association of restless legs syndrome variants in Korean patients with restless legs syndrome. Sleep 2013;36(12):1787–91

    Article  Google Scholar 

  27. Khan FH, Ahlberg CD, Chow CA, Shah DR, Koo BB. Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome. J Neurol 2017;264(8):1634–41

    Article  CAS  Google Scholar 

  28. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54(8):1698–700

    Article  CAS  Google Scholar 

  29. Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 2005;28(9):1069–75

    Article  Google Scholar 

  30. Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, et al. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med 2014;15(11):1288–301

    Article  Google Scholar 

  31. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61(3):304–9

    Article  CAS  Google Scholar 

  32. Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004;62(9):1563–7

    Article  CAS  Google Scholar 

  33. Rizzo G, Manners D, Testa C, Tonon C, Vetrugno R, Marconi S, et al. Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Mov Disord 2013;28(13):1886–90

    Article  Google Scholar 

  34. Snyder AM, Wang X, Patton SM, Arosio P, Levi S, Earley CJ, et al. Mitochondrial ferritin in the substantia nigra in restless legs syndrome. J Neuropathol Exp Neurol 2009;68(11):1193–9

    Article  CAS  Google Scholar 

  35. Comella CL. Treatment of restless legs syndrome. Neurotherapeutics 2014;11(1):177–87

    Article  CAS  Google Scholar 

  36. Becker PM, Novak M. Diagnosis, comorbidities, and management of restless legs syndrome. Curr Med Res Opin 2014;30(8):1441–60

    Article  CAS  Google Scholar 

  37. Hogl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010;257(2):230–7

    Article  Google Scholar 

  38. Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferre S. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med 2018;45:94–7

    Article  Google Scholar 

  39. Oertel W, Trenkwalder C, Benes H, Ferini-Strambi L, Hogl B, Poewe W, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10(8):710–20

    Article  CAS  Google Scholar 

  40. Godau J, Berg D. Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases. Sleep Disord 2011;2011:468952

    Article  Google Scholar 

  41. Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014;370(7):621–31

    Article  CAS  Google Scholar 

  42. Hornyak M, Scholz H, Kohnen R, Bengel J, Kassubek J, Trenkwalder C. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev 2014;18(2):153–64

    Article  Google Scholar 

  43. Garcia-Borreguero D, Cano-Pumarega I. New concepts in the management of restless legs syndrome. BMJ 2017;356:j104

    Article  Google Scholar 

  44. Garcia-Borreguero D, Cano-Pumarega I, Marulanda R. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). Sleep Med Rev 2018;41:50–60

    Article  Google Scholar 

  45. Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 2016;21:1–11

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Christian-Albrechts-Universität zu Kiel, Universitätsklinikum Schleswig Holstein, Arnold Heller Straße 3, Haus 41, 24105, Kiel, Deutschland

    Kirsten E. Zeuner &  Daniela Berg (Direktorin)

Authors
  1. Kirsten E. Zeuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kirsten E. Zeuner.

Additional information

Interessenkonflikt

Die Autorinnen erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. K. Zeuner erklärt Vortrags- und Beratungstätigkeiten für die Firmen Merz, Allergan und Ipsen sowie Unterstützung für wissenschaftliche Projekte. Sie besitzt keine Aktien von Pharmafirmen.D.

Berg erklärt Beratung/Beiratschaft für UCB Pharma und Lundbeck, Honorare für Vortragstätigkeit: UCB Pharma GmbH, Lundbeck, BIAL, Bayer, AbbVie; Fördermittel: Michael J. Fox Stiftung, Janssen Pharmaceutica NV, Deutsche Parkinson-Assoziation (dPV), BMWi, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma, TEVA Pharma, EU, Novartis Pharma, Lundbeck, Damp Stiftung sowie die Anstellung an der Klinik für Neurologie, Universität Kiel, Deutschland und am Hertie-Institut für Klinische Hirnforschung, Tübingen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeuner, K.E., Berg, D. Aktuelle Diagnose- und Therapieoptionen des Restless-Legs-Syndroms. InFo Neurologie 20, 38–46 (2018). https://doi.org/10.1007/s15005-018-2448-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-018-2448-6

Search

Navigation